Traditional bariatric surgery (gastric bypass or sleeve gastrectomy) produces average weight loss of 25 to 35% of starting body weight
Medicare GLP-1 Bridge program Beginning July 1, 2026 through December 31, 2027, eligible Medicare beneficiaries can access the following FDA-approved GLP-1 medications for weight loss : Wegovy (injection or tablet), Foundayo (tablet), and Zepbound (KwikPen only) for $50/month *** through the Medicare GLP-1 Bridge program
(2023) 120:e2212476120
however, each carries some potential side effects to be aware of
Though research is limited, in vitro and in vivo studies have alluded to the potential of semaglutide exerting anti-inflammatory effects by decreasing glucotoxicity, immune cell recruitment, Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-B) and various pro-inflammatory cytokine expression, lipotoxicity, and oxidative stress
This FDA-approved medication is taken just once a week as an injectable to slow digestion and help you feel fuller for longer periods of time
